Clinical Profile Of Drug-Induced Movement Disorders In Cipto Mangunkusumo Hospital, Indonesia
Objective: We aimed to portray the clinical spectrum of Drug-induced movement disorders (DIMDs) in Cipto Mangunkusumo Hospital, Jakarta, Indonesia Background: DIMDs remain a significant burden…Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies
Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of beta-agonist and the risk of PD.…Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.
Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…To be or not to bupropion: a drug-induced parkinsonism?
Objective: To draw attention to drug-induced parkinsonism. Background: Although the main causes of parkinsonism are degenerative, there are some reversible causes, including drug-induced parkinsonism. Method:…Levosulpiride and Movement Disorders–A Growing Concern
Objective: To describe a series of patients with levosulpiride (LVS) induced movement disorders (LIM) evaluated at a single movement disorder center, the All India Institute…A STUDY OF CLINICAL SPECTRUM, RISK FACTORS AND OUTCOME OF DRUG-INDUCED MOVEMENT DISORDERS
Objective: We aimed to characterize the spectrum of DIMDs, and the culprit agents commonly encountered in the movement disorder clinic. We also set out to…Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report
Objective: Neuroleptic malignant syndrome (NMS) is a neurological emergency that is often induced by antipsychotic drugs. NMS may be mortal if left untreated. Background: In…Novel Antipsychotics and Risk of Drug-Induced Movement Disorders and Tardive Syndromes
Objective: To review evidence on the risk of drug-induced movement disorders (DIMDs) with newer antipsychotic (AP) drugs. Background: DIMDs, both acute/subacute “extrapyramidal symptoms” and chronic…Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease
Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database
Objective: Objective: Drug-disease interactions in Parkinson's disease patients can give rise to situations where a drug may have negative effects on both motor- and non-motor…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »